Liposomal doxorubicin is a chemotherapeutic medication that contains doxorubicin (Adriamycin) and is wrapped in a fatty shell known as a liposome. Doxorubicin inhibits topoisomerase 2, an enzyme required by cancer cells to divide and proliferate.
Liposomal doxorubicin is doxorubicin that has been encapsulated in small spheres known as pegylated liposomes. These spheres maintain doxorubicin in the circulation for longer, allowing more of the medicine to reach cancer cells. It is used to treat cancers such as breast cancer, ovarian cancer, Kaposi's sarcoma, and multiple myeloma.
In recent years, the global liposomal doxorubicin market has witnessed a series of product launches and approvals that have contributed to its growth. DataM Intelligence's in-depth market analysis reveals the major image recognition market drivers, challenges, trends, and opportunities.
Our market intelligence report evaluates the market size, growth, and share, providing crucial insights for businesses to make informed decisions and capitalize on the existing and upcoming opportunities in the liposomal doxorubicin market.
Exploring Market Drivers and Restraints
The Rising Prevalence of Cancer Globally And Increasing Number of Companies Manufacturing Doxorubicin Are Expected to Drive Market Growth
The global liposomal doxorubicin market is being driven by an increase in cancer incidence. According to the World Health Organization (WHO), cancer accounts for 13% of all deaths worldwide each year.
Furthermore, cancer occurrences are expected to rise by 70% over the next two decades, and the worldwide elderly population is expected to almost double from 12% to 22% between 2015 and 2022. The global incidence of all cancer types is expected to rise at a 2.5% CAGR between 2015 and 2030. Cancer mortality is expected to rise at a faster pace than cancer incidence between 2015 and 2030, with a CAGR of 2.6%.
Side Effects Associated With Doxorubicin is Expected to Hamper The Market Growth
Some negative effects associated with liposomal doxorubicin are projected to impede market expansion throughout the projection period. Some of the adverse effects include an increased risk of infection, shortness of breath and pallor, bruises, bleeding gums and nosebleeds, weariness and weakness (fatigue) during and after treatment, as well as discomfort, redness, and peeling of your hands and feet.
Market Key Players
The liposomal doxorubicin market is highly competitive with the presence of a large number of major players.
- Johnson & Johnson
- SRS Pharmaceuticals Pvt. Ltd.
- Sun Pharmaceutical Industries Ltd.
- Cadila Pharmaceuticals
Key industry players are focused on product developments, new product launches, and geographical expansions to gain a significant amount of market share.
For businesses, investors, and decision-makers in the liposomal doxorubicin market, conducting a thorough market analysis is crucial in staying ahead of the competition.
To Gain a deeper understanding of the liposomal doxorubicin market, DataM Intelligence offers a comprehensive market analysis report encompassing the latest trends, opportunities, and challenges. Discover how this rapidly evolving market can impact your business and investment decisions.
To Know More Download Sample
